摘要
目的分析特瑞普利单抗联合多西他赛+顺铂+氟尿嘧啶(DPF)化疗对食管鳞状细胞癌(ESCC)患者血清神经元特异性烯醇化酶(NSE)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、胃泌素释放肽前体(ProGRP)的影响。方法将80例ESCC患者随机均分为特瑞普利单抗联合组和常规DPF化疗组,常规DPF化疗组使用常规化疗方案,特瑞普利单抗联合组在常规DPF化疗组基础上使用特瑞普利单抗治疗。治疗4个周期后观察两组临床疗效、不良反应以及治疗前后NSE、CYFRA21-1、ProGRP和常规肿瘤标志物指标[甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)]水平。结果特瑞普利单抗联合组的客观缓解率(ORR)和疾病控制率(DCR)均高于常规DPF化疗组(P<0.05)。两组不良反应发生率比较,差异无显著性(P>0.05)。治疗后,两组NSE、CYFRA21-1、ProGRP以及常规肿瘤标志物指标水平均降低,且特瑞普利单抗联合组低于常规DPF化疗组(P<0.05)。结论特瑞普利单抗联合DPF化疗对ESCC的疗效确切,可以有效提高ORR和DCR,降低NSE、CYFRA21-1、ProGRP及常规肿瘤标志物指标水平,且不会增加患者的不良反应。
Aim To analyze the effects of toripalimab combined with docetaxel+cisplatin+fluorouracil(DPF)chemotherapy on serum neuron-specific enolase(NSE),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),and gastrin-releasing peptide precursor(ProGRP)in patients with esophageal squamous cell carcinoma(ESCC).Methods A total of 80 ESCC patients were randomly and equally divided into the toripalimab combination group and the conventional DPF chemotherapy group.The conventional DPF chemotherapy group received standard chemotherapy regimens,while the toripalimab combination group was treated with toripalimab in addition to the conventional DPF chemotherapy regimen.After 4 treatment cycles,the clinical efficacy,adverse reactions,and levels of NSE,CYFRA21-1,ProGRP,and conventional tumor markers[alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)]were compared between the two groups before and after treatment.Results The objective response rate(ORR)and disease control rate(DCR)in the toripalimab combination group were higher than those in the conventional DPF chemotherapy group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of NSE,CYFRA21-1,ProGRP,and conventional tumor marker indicators were decreased in both groups,with the toripalimab combination group showing lower levels than the conventional DPF chemotherapy group(P<0.05).Conclusion The combination of trastuzumab and DPF chemotherapy has a definite therapeutic effect on ESCC,which can effectively improve ORR and DCR,reduce the levels of NSE,CYFRA21-1,ProGRP,and conventional tumor markers in patients,and does not increase adverse reactions.
作者
方家祥
刘萌
江畅
FANG Jiaxiang;LIU Meng;JIANG Chang(Lu'an Hospital of Traditional Chinese Medicine,Lu'an 237000,Anhui,China;Department of Pharmacy,Lu'an People's Hospital,Lu'an 237000,Anhui,China)
出处
《中南医学科学杂志》
2025年第4期629-632,共4页
Medical Science Journal of Central South China
基金
安徽省重点研究与开发计划项目(2022e07020069)。
